BioCentury
ARTICLE | Clinical News

LX7101: Phase I data

August 27, 2012 7:00 AM UTC

A double-blind, placebo-controlled, U.S. Phase I trial in 63 patients with glaucoma showed that 0.125% and 0.25% doses of LX7101 for 2 weeks were well tolerated with no serious adverse events or withd...